JP2023545497A5 - - Google Patents
Info
- Publication number
- JP2023545497A5 JP2023545497A5 JP2023522972A JP2023522972A JP2023545497A5 JP 2023545497 A5 JP2023545497 A5 JP 2023545497A5 JP 2023522972 A JP2023522972 A JP 2023522972A JP 2023522972 A JP2023522972 A JP 2023522972A JP 2023545497 A5 JP2023545497 A5 JP 2023545497A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- modified
- amino acid
- seq
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091891P | 2020-10-14 | 2020-10-14 | |
| US63/091,891 | 2020-10-14 | ||
| US202163248081P | 2021-09-24 | 2021-09-24 | |
| US63/248,081 | 2021-09-24 | ||
| PCT/US2021/055057 WO2022081890A1 (en) | 2020-10-14 | 2021-10-14 | Compositions and methods for treating glycogen storage disease type 1a |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023545497A JP2023545497A (ja) | 2023-10-30 |
| JP2023545497A5 true JP2023545497A5 (cg-RX-API-DMAC7.html) | 2024-10-23 |
Family
ID=81208619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023522972A Pending JP2023545497A (ja) | 2020-10-14 | 2021-10-14 | グリコーゲン貯蔵症1a型を治療するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230383277A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4229195A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023545497A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230124553A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021360919A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198671A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022081890A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| CN114096666B (zh) | 2019-02-13 | 2025-03-18 | 比姆医疗股份有限公司 | 治疗血红素病变的组合物和方法 |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| WO2025194124A1 (en) * | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | Modified st1cas9 guide nucleic acids |
| WO2026143185A1 (en) | 2024-12-23 | 2026-07-02 | Ensoma Aps | Engineered rna-guided dna-binding polypeptides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102894715B1 (ko) * | 2018-08-03 | 2025-12-03 | 빔 테라퓨틱스, 인크. | 핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법 |
| EP3850088A4 (en) * | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| KR20210055733A (ko) * | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| WO2020163396A1 (en) * | 2019-02-04 | 2020-08-13 | The General Hospital Corporation | Adenine dna base editor variants with reduced off-target rna editing |
| US12600971B2 (en) * | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| US20220127594A1 (en) * | 2019-02-13 | 2022-04-28 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| WO2020168135A1 (en) * | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| KR20240037299A (ko) * | 2021-07-23 | 2024-03-21 | 빔 테라퓨틱스, 인크. | Crispr/cas 편집 시스템용 가이드 rna |
-
2021
- 2021-10-14 US US18/031,547 patent/US20230383277A1/en active Pending
- 2021-10-14 WO PCT/US2021/055057 patent/WO2022081890A1/en not_active Ceased
- 2021-10-14 CA CA3198671A patent/CA3198671A1/en active Pending
- 2021-10-14 EP EP21881115.6A patent/EP4229195A4/en active Pending
- 2021-10-14 KR KR1020237016287A patent/KR20230124553A/ko active Pending
- 2021-10-14 JP JP2023522972A patent/JP2023545497A/ja active Pending
- 2021-10-14 AU AU2021360919A patent/AU2021360919A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230026726A1 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
| AU2020223733B2 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| US20230018543A1 (en) | Crispr/cas-mediated gene conversion | |
| JP2022546608A5 (cg-RX-API-DMAC7.html) | ||
| US20210380987A1 (en) | Crispr/cas-related methods and compositions for treating cystic fibrosis | |
| JP2026064992A (ja) | β異常ヘモグロビン症を治療するためのCRISPR/CAS関連方法および組成物 | |
| JP2025170240A5 (cg-RX-API-DMAC7.html) | ||
| US20170007679A1 (en) | Crispr/cas-related methods and compositions for treating hiv infection and aids | |
| JP2022545950A5 (cg-RX-API-DMAC7.html) | ||
| CA3052275A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| JP2024534945A (ja) | 化学修飾を有するプライム編集のためのガイドrna | |
| WO2015148860A1 (en) | Crispr/cas-related methods and compositions for treating beta-thalassemia | |
| AU2020221355A1 (en) | Compositions and methods for treating glycogen storage disease type 1a | |
| JP2022532139A5 (cg-RX-API-DMAC7.html) | ||
| US20230340468A1 (en) | Methods for using guide rnas with chemical modifications | |
| JP2024511621A5 (cg-RX-API-DMAC7.html) | ||
| JP2021522825A5 (cg-RX-API-DMAC7.html) | ||
| JP2023507034A5 (cg-RX-API-DMAC7.html) |